PD-1⁺regulatory T cells amplified by PD-1 b
of cancer

Proceedings of the National Academy of Sciences of the Unite
116, 9999-10008
DOI: 10.1073/pnas.1822001116

Citation Report

#	Article	IF	Citations
1	Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells. Journal of Autoimmunity, 2019, 104, 102310.	3.0	57
2	Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?. Immunotherapy, 2019, 11, 1149-1160.	1.0	9
3	The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy. Genome Medicine, 2019, 11, 43.	3.6	16
4	Targeting Treg cells in cancer immunotherapy. European Journal of Immunology, 2019, 49, 1140-1146.	1.6	303
5	Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1. Journal of Experimental and Clinical Cancer Research, 2019, 38, 432.	3.5	74
6	Cell-by-cell deciphering of T cells in allergic inflammation. Journal of Allergy and Clinical Immunology, 2019, 144, 1143-1148.	1.5	13
7	Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 1699.	1.7	81
8	Immune Cell Infiltration Influences Long-Term Survivorship of Patients with SCLC. Journal of Thoracic Oncology, 2019, 14, e241.	0.5	5
10	Sequential MR Imageâ€Guided Local Immune Checkpoint Blockade Cancer Immunotherapy Using Ferumoxytol Capped Ultralarge Pore Mesoporous Silica Carriers after Standard Chemotherapy. Small, 2019, 15, e1904378.	5.2	36
11	Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. Blood, 2019, 134, 1406-1414.	0.6	80
12	The Diverse Function of PD-1/PD-L Pathway Beyond Cancer. Frontiers in Immunology, 2019, 10, 2298.	2.2	244
13	Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression. International Journal of Molecular Sciences, 2019, 20, 4719.	1.8	48
14	Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. Cancer Science, 2019, 110, 2080-2089.	1.7	614
15	Regulatory T cells in cancer: where are we now?. Immunology, 2019, 157, 187-189.	2.0	16
16	Hyperprogression during immunotherapy: do we really want to know?. Annals of Oncology, 2019, 30, 1028-1031.	0.6	17
17	Microbiota: Overview and Implication in Immunotherapy-Based Cancer Treatments. International Journal of Molecular Sciences, 2019, 20, 2699.	1.8	26
18	Hyperprogression under Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 2674.	1.8	96
19	Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer. Translational Cancer Research, 2019, 8, S628-S632.	0.4	3

#	Article	IF	Citations
20	T-Regulatory Cells In Tumor Progression And Therapy . Cancer Management and Research, 2019, Volume 11, 10731-10747.	0.9	57
21	Traitements de premiÃ¨re ligne dans les CBNPC avancÃ©s, en lâ€™absence dâ€™addiction oncogÃ©nique (incluant) Tj ETQq1 1 0.784 2019, 11, 342-354.	0.0	0
22	How to recognize and manage hyper-progression and pseudo- progression during immune checkpoint blockade in non-small cell lung cancer. Precision Cancer Medicine, 2019, 2, 35-35.	1.8	3
23	CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. , 2019, 7, 304.		181
24	Immune Checkpoints in Circulating and Tumor-Infiltrating CD4+ T Cell Subsets in Colorectal Cancer Patients. Frontiers in Immunology, 2019, 10, 2936.	2.2	97
25	Editorial: Lymphocyte Functional Crosstalk and Regulation. Frontiers in Immunology, 2019, 10, 2916.	2.2	6
26	Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. Expert Review of Endocrinology and Metabolism, 2019, 14, 381-398.	1.2	54
27	Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer. Anti-Cancer Drugs, 2019, 30, 1067-1070.	0.7	5
28	Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. Nature Communications, 2019, 10, 5546.	5.8	98
29	The pro-tumorigenic host response to cancer therapies. Nature Reviews Cancer, 2019, 19, 667-685.	12.8	135
30	Current state of nonengrafting donor leukocyte infusion (focus on microtransplantation for acute) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.2	3
31	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers, 2019, 11, 1926.	1.7	27
32	Response to Letter to the Editor. Journal of Thoracic Oncology, 2019, 14, e261-e262.	0.5	0
33	Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. Human Vaccines and Immunotherapeutics, 2020, 16, 112-115.	1.4	47
34	Understanding genetic determinants of resistance to immune checkpoint blockers. Seminars in Cancer Biology, 2020, 65, 123-139.	4.3	9
35	The potential application of PD-1 blockade therapy for early-stage biliary tract cancer. International Immunology, 2020, 32, 273-281.	1.8	10
36	Molecular imaging biomarkers for immune checkpoint inhibitor therapy. Theranostics, 2020, 10, 1708-1718.	4.6	68
37	Impact of Viral Etiologies on the Development of Novel Immunotherapy for Hepatocellular Carcinoma. Seminars in Liver Disease, 2020, 40, 131-142.	1.8	3

#	Article	IF	Citations
38	Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer. Oral Oncology, 2020, 100, 104477.	0.8	9
39	Pembrolizumab Interferes with the Differentiation of Human FOXP3+â€“Induced T Regulatory Cells, but Not with FOXP3 Stability, through Activation of mTOR. Journal of Immunology, 2020, 204, 199-211.	0.4	17
40	Immune checkpoint blockade: an urgent call for biomarkers to help guide treatment. British Journal of Dermatology, 2020, 182, 1085-1086.	1.4	0
41	CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy. Cancer Immunology Research, 2020, 8, 334-344.	1.6	155
42	Hyperprogressive Disease in Patients with Nonâ€“Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of ¹⁸F-FDG PET/CT. Journal of Nuclear Medicine, 2020, 61, 821-826.	2.8	73
43	Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Science Immunology, 2020, 5, .	5.6	148
44	Treatment after progression in the era of immunotherapy. Lancet Oncology, The, 2020, 21, e463-e476.	5.1	115
45	Is Weak Acid Beneficial for Addressing Checkpoint Inhibitorâ€“Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?. Cancer Control, 2020, 27, 107327482094429.	0.7	2
46	The association between monocytic myeloid-derived suppressor cells levels and the anti-tumor efficacy of anti-PD-1 therapy in NSCLC patients. Translational Oncology, 2020, 13, 100865.	1.7	12
47	Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions . Cancer Management and Research, 2020, Volume 12, 10411-10421.	0.9	14
48	Intrahepatic TH17/TReg Cells in Homeostasis and Diseaseâ€”Itâ€™s All About the Balance. Frontiers in Pharmacology, 2020, 11, 588436.	1.6	23
49	Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. Cancers, 2020, 12, 2870.	1.7	64
51	Immune escape: A critical hallmark in solid tumors. Life Sciences, 2020, 258, 118110.	2.0	91
52	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Nonâ€“Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy. JCO Precision Oncology, 2020, 4, 829-840.	1.5	25
53	Relevance of Regulatory T Cells during Colorectal Cancer Development. Cancers, 2020, 12, 1888.	1.7	34
54	Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy. , 2020, 8, e000967.		67
55	Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Molecular Cancer, 2020, 19, 116.	7.9	384
56	AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. Cell Death Discovery, 2020, 6, 57.	2.0	41

#	Article	IF	Citations
57	Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma. Cancer Biology and Therapy, 2020, 21, 1097-1104.	1.5	7
58	Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. Frontiers in Oncology, 2020, 10, 590058.	1.3	5
59	Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (donâ€™t) know. Journal of Experimental and Clinical Cancer Research, 2020, 39, 236.	3.5	44
60	Programmed Cell Death Ligand (PD-L)-1 Contributes to the Regulation of CD4+ T Effector and Regulatory T Cells in Cutaneous Leishmaniasis. Frontiers in Immunology, 2020, 11, 574491.	2.2	13
61	Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies. Frontiers in Oncology, 2020, 10, 582884.	1.3	23
62	Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis. BMC Cancer, 2020, 20, 707.	1.1	23
63	PD-L1 Is Expressed and Promotes the Expansion of Regulatory T Cells in Acute Myeloid Leukemia. Frontiers in Immunology, 2020, 11, 1710.	2.2	44
64	An emerging role of regulatory T-cells in cardiovascular repair and regeneration. Theranostics, 2020, 10, 8924-8938.	4.6	25
65	Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors. Cells, 2020, 9, 1727.	1.8	8
66	CD4+CD126low/âˆ' Foxp3+ Cell Population Represents a Superior Subset of Regulatory T Cells in Treating Autoimmune Diseases. Molecular Therapy, 2020, 28, 2406-2416.	3.7	9
67	Atypical patterns of response and progression in the era of immunotherapy combinations. Future Oncology, 2020, 16, 1707-1713.	1.1	11
68	â€œAge Related Differences in the Biology of Chronic Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantationâ€• Frontiers in Immunology, 2020, 11, 571884.	2.2	16
69	Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. Signal Transduction and Targeted Therapy, 2020, 5, 250.	7.1	86
70	The critical role of CD4+ T cells in PD-1 blockade against MHC-IIâ€“expressing tumors such as classic Hodgkin lymphoma. Blood Advances, 2020, 4, 4069-4082.	2.5	76
71	Higher Frequency and Increased Expression of Molecules Associated with Suppression on T Regulatory Cells from Newborn Compared with Adult Nonhuman Primates. Journal of Immunology, 2020, 205, 2128-2136.	0.4	8
72	Fixed drug eruption dramatically exacerbated during treatment with programmed death 1 inhibitor. Journal of Dermatology, 2020, 47, e425-e426.	0.6	1
73	Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy. Current Oncology Reports, 2020, 22, 116.	1.8	9
74	The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nature Immunology, 2020, 21, 1346-1358.	7.0	431

#	Article	IF	Citations
75	Selective inhibition of TGF-Î²1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer. Nature Communications, 2020, 11, 4545.	5.8	94
76	Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells. Science Translational Medicine, 2020, 12, .	5.8	89
77	Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. Biomedicines, 2020, 8, 617.	1.4	14
78	Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. Respiration, 2020, 99, 903-929.	1.2	18
79	Transcriptional Control of Regulatory T Cells in Cancer: Toward Therapeutic Targeting?. Cancers, 2020, 12, 3194.	1.7	6
80	The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy. Molecular Cancer, 2020, 19, 81.	7.9	82
81	Heterogeneity of exhausted T cells in the tumor microenvironment is linked to patient survival following resection in hepatocellular carcinoma. OncoImmunology, 2020, 9, 1746573.	2.1	21
82	Harnessing proteases for T regulatory cell immunotherapy. European Journal of Immunology, 2020, 50, 770-778.	1.6	4
83	Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy. BioDrugs, 2020, 34, 463-476.	2.2	49
84	Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses. Frontiers in Oncology, 2020, 10, 515.	1.3	20
85	Immune checkpoint signaling and cancer immunotherapy. Cell Research, 2020, 30, 660-669.	5.7	617
86	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. Frontiers in Immunology, 2020, 11, 784.	2.2	339
87	IRE1Î± regulates macrophage polarization, PD-L1 expression, and tumor survival. PLoS Biology, 2020, 18, e3000687.	2.6	42
88	Peptide Vaccine Combined Adjuvants Modulate Anti-tumor Effects of Radiation in Glioblastoma Mouse Model. Frontiers in Immunology, 2020, 11, 1165.	2.2	14
89	RNA binding protein PCBP1 is an intracellular immune checkpoint for shaping T cell responses in cancer immunity. Science Advances, 2020, 6, eaaz3865.	4.7	32
90	Resolving the HIF paradox in pancreatic cancer. Cancer Letters, 2020, 489, 50-55.	3.2	9
91	Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells. Lung Cancer, 2020, 146, 86-96.	0.9	14
92	Cisplatin plus pemetrexed therapy and subsequent immune checkpoint inhibitor administration for malignant peritoneal mesothelioma without pleural lesions. Medicine (United States), 2020, 99, e19956.	0.4	5

#	Article	IF	Citations
93	Effects of adaptive immune cell therapy on the immune cell profile in patients with advanced gastric cancer. Cancer Medicine, 2020, 9, 4907-4917.	1.3	2
94	Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer. Gastric Cancer, 2020, 23, 893-903.	2.7	20
95	Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma. BMC Cancer, 2020, 20, 229.	1.1	30
96	Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6640-6650.	3.3	141
97	Bidirectional signals of PD-L1 in T cells that fraternize with cancer cells. Nature Immunology, 2020, 21, 365-366.	7.0	14
98	How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?. Frontiers in Immunology, 2020, 11, 492.	2.2	40
99	T cell costimulation, checkpoint inhibitors and anti-tumor therapy. Journal of Biosciences, 2020, 45, 1.	0.5	24
100	Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer. British Journal of Cancer, 2020, 123, 965-972.	2.9	53
101	An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. Immunity, 2020, 53, 187-203.e8.	6.6	119
102	Hyperprogressive disease in patients with advanced renal cell carcinoma: a new pattern of post-treatment cancer behavior. Immunologic Research, 2020, 68, 204-212.	1.3	5
103	Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy. Immune Network, 2020, 20, e4.	1.6	75
104	Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, , .	0.8	3
105	Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. Cancers, 2020, 12, 344.	1.7	60
106	Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature. Oncologist, 2020, 25, 369-374.	1.9	13
107	Distribution of Regulatory T-Cells and Other Phenotypes of T-Cells in Tumors and Regional Lymph Nodes of Colorectal Cancer Patients. In Vivo, 2020, 34, 849-856.	0.6	9
108	Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?. Oncologist, 2020, 25, 94-98.	1.9	58
110	Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells. BMC Cancer, 2020, 20, 25.	1.1	75
111	Development of a protein-based system for transient epigenetic repression of immune checkpoint molecule and enhancement of antitumour activity of natural killer cells. British Journal of Cancer, 2020, 122, 823-834.	2.9	6

#	Article	IF	Citations
112	Role of heterogeneous regulatory T cells in the tumor microenvironment. Pharmacological Research, 2020, 153, 104659.	3.1	23
113	Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?. Trends in Cancer, 2020, 6, 181-191.	3.8	82
114	Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). Journal of Clinical Oncology, 2020, 38, 2053-2061.	0.8	469
115	Transcriptional regulation of Treg homeostasis and functional specification. Cellular and Molecular Life Sciences, 2020, 77, 4269-4287.	2.4	16
116	Modulation of regulatory T cell function and stability by co-inhibitory receptors. Nature Reviews Immunology, 2020, 20, 680-693.	10.6	127
117	Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma. Scientific Reports, 2020, 10, 6220.	1.6	25
118	Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study. Journal of Immunotherapy, 2020, 43, 139-144.	1.2	61
119	JunB Controls Intestinal Effector Programs in Regulatory T Cells. Frontiers in Immunology, 2020, 11, 444.	2.2	9
120	Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?. Frontiers in Pharmacology, 2020, 11, 441.	1.6	48
121	A CT-based radiomics signature for evaluating tumor infiltrating Treg cells and outcome prediction of gastric cancer. Annals of Translational Medicine, 2020, 8, 469-469.	0.7	16
122	Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer. Targeted Oncology, 2020, 15, 241-247.	1.7	33
123	Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Nonâ€“small Cell Lung Cancer. Current Oncology Reports, 2020, 22, 41.	1.8	20
124	Hyperprogression Under Immune Checkpoint-Based Immunotherapyâ€"Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model. Cancers, 2020, 12, 804.	1.7	19
125	Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies. International Journal of Molecular Sciences, 2020, 21, 2411.	1.8	28
126	Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et alâ€™s Letter to the Editor re: Alfonso GÃ³mez de LiaÃ±o Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Antiâ€“PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269â€“76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation. European Urology, 2021, 79, e20-e21.	0.9	0
127	A melanoma patient obtained sustained survival benefit from anti-PD-1 therapy in spite of MDM2 amplification. Oral Oncology, 2021, 113, 105023.	0.8	0
128	Synergism between anti-angiogenic and immune checkpoint inhibitor drugs: A hypothesis. Medical Hypotheses, 2021, 146, 110399.	0.8	5
129	The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities. Frontiers in Immunology, 2020, 11, 585819.	2.2	23

#	Article	IF	Citations
130	Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways. Critical Reviews in Oncology/Hematology, 2021, 157, 103164.	2.0	40
131	Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer. Clinical Cancer Research, 2021, 27, 1029-1036.	3.2	46
132	The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cellular and Molecular Immunology, 2021, 18, 279-293.	4.8	102
133	Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview. Pharmacological Research, 2021, 164, 105309.	3.1	12
134	Cross talk between human regulatory T cells and antigenâ€presenting cells: Lessons for clinical applications. European Journal of Immunology, 2021, 51, 27-38.	1.6	17
135	Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy. European Journal of Immunology, 2021, 51, 280-291.	1.6	68
136	Hyperprogressive disease in patients receiving immune checkpoint inhibitors. Current Problems in Cancer, 2021, 45, 100688.	1.0	5
137	The Multifaceted Role of Regulatory T Cells in Breast Cancer. Annual Review of Cancer Biology, 2021, 5, 291-310.	2.3	24
138	Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors. International Journal of Cancer, 2021, 149, 277-286.	2.3	7
139	Current status of immunotherapy for advanced gastric cancer. Japanese Journal of Clinical Oncology, 2021, 51, 20-27.	0.6	43
140	SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment. Journal of Immunology, 2021, 206, 193-205.	0.4	40
141	Hemagglutinating virus of Japanâ€envelope containing programmed cell deathâ€ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma. Cancer Science, 2021, 112, 81-90.	1.7	9
142	Tumor-infiltrating lymphocytes in the immunotherapy era. Cellular and Molecular Immunology, 2021, 18, 842-859.	4.8	403
143	The tumor-promoting effects of the adaptive immune system: a cause of hyperprogressive disease in cancer?. Cellular and Molecular Life Sciences, 2021, 78, 853-865.	2.4	8
144	Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma. Cancer Immunology, Immunotherapy, 2021, 70, 1491-1496.	2.0	15
145	Understanding and Targeting Human Cancer Regulatory T Cells to Improve Therapy. Advances in Experimental Medicine and Biology, 2021, 1278, 229-256.	0.8	5
146	An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth. Cancer Discovery, 2021, 11, 696-713.	7.7	34
147	Therapeutic efficacy of dendritic cell vaccine combined with programmed death 1 inhibitor for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1988-1996.	1.4	18

#	Article	IF	Citations
148	IFN-Î³ and CD38 in Hyperprogressive Cancer Development. Cancers, 2021, 13, 309.	1.7	17
149	A Case of a Metastatic Small Bowel Tumor Resected during Chemotherapy for Reccurent Malignat Melanoma of the Nasal Cavity. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical) Tj ETQq1 1 0.784314 rg BT /Overlock 10 Tf	0.0	0
150	Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. OncoImmunology, 2021, 10, 1973710.	2.1	4
151	PD-1 Blockade Aggravates Epsteinâ€"Barr Virus+ Post-Transplant Lymphoproliferative Disorder in Humanized Mice Resulting in Central Nervous System Involvement and CD4+ T Cell Dysregulations. Frontiers in Oncology, 2020, 10, 614876.	1.3	19
152	Rapamycin attenuates gene expression of programmed cell death protein-ligand 1 and Foxp3 in the brain; a novel mechanism proposed for immunotherapy in the brain. Research in Pharmaceutical Sciences, 2021, 16, 165.	0.6	1
153	A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation. Respiratory Medicine Case Reports, 2021, 33, 101405.	0.2	6
154	Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab. Oncotarget, 2021, 12, 2131-2146.	0.8	3
155	Oxidative Stress in the Tumor Immune Microenvironment. , 2021, , 27-54.		1
156	Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection. Journal of Clinical Medicine, 2021, 10, 221.	1.0	11
157	The liposome of trehalose dimycolate extracted from M.Âbovis BCG induces antitumor immunity via the activation of dendritic cells and CD8+ T cells. Cancer Immunology, Immunotherapy, 2021, 70, 2529-2543.	2.0	15
158	Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nature Medicine, 2021, 27, 212-224.	15.2	376
159	Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nature Communications, 2021, 12, 832.	5.8	248
160	Downâ€regulation of RCC1 sensitizes immunotherapy by upâ€regulating PDâ€L1 via p27^{kip1}/CDK4 axis in nonâ€small cell lung cancer. Journal of Cellular and Molecular Medicine, 2021, 25, 4136-4147.	1.6	12
161	Immunotherapy for the treatment of colorectal cancer. Journal of Surgical Oncology, 2021, 123, 760-774.	0.8	18
162	Hyperprogressive Disease After Pembrolizumab Treatment in Advanced Epstein-Barr Virusâ€"Associated Gastric Adenocarcinoma With ERBB2 Amplification. JCO Precision Oncology, 2021, 5, 370-377.	1.5	2
163	Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. Lung Cancer, 2021, 152, 109-118.	0.9	14
164	Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. Journal of Experimental and Clinical Cancer Research, 2021, 40, 74.	3.5	19
165	Succinylation Regulators Promote Clear Cell Renal Cell Carcinoma by Immune Regulation and RNA N6-Methyladenosine Methylation. Frontiers in Cell and Developmental Biology, 2021, 9, 622198.	1.8	13

#	Article	IF	Citations
166	Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation. Scientific Reports, 2021, 11, 4030.	1.6	10
167	Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy. Frontiers in Immunology, 2020, 11, 561083.	2.2	12
168	The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies. Frontiers in Immunology, 2021, 12, 625783.	2.2	34
169	Combined antiâ€PDâ€1 and antiâ€CTLAâ€4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. European Journal of Immunology, 2021, 51, 544-556.	1.6	71
170	A new predictive biomarker enables more accurate PD-1 blockade therapy. Cellular and Molecular Immunology, 2021, 18, 1624-1625.	4.8	0
171	Non-canonical PD-1 signaling in cancer and its potential implications in clinic. , 2021, 9, e001230.		15
172	Tumour angiogenesis normalized by myoâ€inositol trispyrophosphate alleviates hypoxia in the microenvironment and promotes antitumor immune response. Journal of Cellular and Molecular Medicine, 2021, 25, 3284-3299.	1.6	15
173	Therapeutic depletion of CCR8⁺tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy. , 2021, 9, e001749.		91
174	Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nature Reviews Clinical Oncology, 2021, 18, 473-487.	12.5	139
175	Nanobiomaterial-based vaccination immunotherapy of cancer. Biomaterials, 2021, 270, 120709.	5.7	77
176	Single-Cell Sequencing Reveals the Transcriptome and TCR Characteristics of pTregs and in vitro Expanded iTregs. Frontiers in Immunology, 2021, 12, 619932.	2.2	9
177	Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy. Frontiers in Oncology, 2021, 11, 626818.	1.3	13
178	Newly diagnosed follicular lymphoma during pembrolizumab treatment for lung cancer. International Journal of Hematology, 2021, 114, 280-285.	0.7	2
180	Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors. JAMA Network Open, 2021, 4, e211136.	2.8	43
181	Outcomes on <scp>antiâ€VEGFR</scp>â€2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. International Journal of Cancer, 2021, 149, 378-386.	2.3	14
182	Trifluridine/tipiracil plus ramucirumab in gastric cancer. The Lancet Gastroenterology and Hepatology, 2021, 6, 154-155.	3.7	1
183	CD11c-CD8 Spatial Cross Presentation: A Novel Approach to Link Immune Surveillance and Patient Survival in Soft Tissue Sarcoma. Cancers, 2021, 13, 1175.	1.7	2
184	Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer. Scientific Reports, 2021, 11, 6956.	1.6	3

#	Article	IF	Citations
185	Hyperprogressive disease after radiotherapy combined with anti-PD-1 therapy in renal cell carcinoma: a case report and review of the literature. BMC Urology, 2021, 21, 42.	0.6	6
186	Fast progression in nonâ€"small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. , 2021, 9, e001882.		12
187	Recruitment and Expansion of Tregs Cells in the Tumor Environmentâ€"How to Target Them?. Cancers, 2021, 13, 1850.	1.7	38
188	Hyperprogressive Disease: Main Features and Key Controversies. International Journal of Molecular Sciences, 2021, 22, 3736.	1.8	18
189	CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade. Cancers, 2021, 13, 1935.	1.7	15
190	Anti-PD-1 Immunotherapy and Bee Venom for Relapsed and Refractory Liposarcoma: A Case Report. Frontiers in Oncology, 2021, 11, 668992.	1.3	3
191	Anti-angiogenic agents â€" overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nature Reviews Clinical Oncology, 2021, 18, 527-540.	12.5	162
192	Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas. Blood Reviews, 2021, 50, 100832.	2.8	5
193	Novel therapies targeting cutaneous T cell lymphomas and their microenvironment. Seminars in Hematology, 2021, 58, 103-113.	1.8	4
194	Case Report: Immune Checkpoint Inhibitor-Induced Exuberant Tumor Inflammation With Accelerated Clinical Deterioration in Metastatic Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 679177.	1.3	3
195	A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Science Translational Medicine, 2021, 13, .	5.8	59
196	Post-Translational Regulations of Foxp3 in Treg Cells and Their Therapeutic Applications. Frontiers in Immunology, 2021, 12, 626172.	2.2	34
197	Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 4710.	1.8	22
198	Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature. Frontiers in Immunology, 2021, 12, 608292.	2.2	10
199	Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy. Gut, 2022, 71, 734-745.	6.1	177
200	Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nature Communications, 2021, 12, 2582.	5.8	96
201	Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer. Vaccines, 2021, 9, 454.	2.1	11
202	Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer. JCI Insight, 2021, 6, .	2.3	17

#	Article	IF	Citations
203	Emerging concepts in PD-1 checkpoint biology. Seminars in Immunology, 2021, 52, 101480.	2.7	84
204	Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition. Acta Pharmacologica Sinica, 2022, 43, 672-680.	2.8	33
205	The Role of Programmed Death-1 in Type 1 Diabetes. Current Diabetes Reports, 2021, 21, 20.	1.7	11
206	Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 669474.	2.2	124
207	Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy. Medicine (United States), 2021, 100, e25773.	0.4	7
208	IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment. Frontiers in Immunology, 2021, 12, 683332.	2.2	20
209	METTL14 Acts as a Potential Regulator of Tumor Immune and Progression in Clear Cell Renal Cell Carcinoma. Frontiers in Genetics, 2021, 12, 609174.	1.1	11
210	The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells. Seminars in Cancer Biology, 2022, 86, 1045-1055.	4.3	17
211	TIGIT modulates sepsis-induced immune dysregulation in mice with preexisting malignancy. JCI Insight, 2021, 6, .	2.3	14
212	Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells. International Immunology, 2021, 33, 435-446.	1.8	14
213	The importance of sPD-1, sOX40L and sGITR in terms of clinicopathology and histopathology in gastric cancer. Turkish Journal of Biochemistry, 2021, .	0.3	1
214	The PDâ€1 Interactome. Advanced Biology, 2021, 5, e2100758.	1.4	21
215	Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[<i>c</i>][1,2,5]oxadiazole Derivatives as Potent PD-L1 Inhibitors with <i>In Vivo</i> Antitumor Activity. Journal of Medicinal Chemistry, 2021, 64, 8391-8409.	2.9	29
216	Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy. Molecular Neurodegeneration, 2021, 16, 39.	4.4	13
217	The Curcumin Analog GO-Y030 Controls the Generation and Stability of Regulatory T Cells. Frontiers in Immunology, 2021, 12, 687669.	2.2	16
218	Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Science Advances, 2021, 7, .	4.7	56
219	TGF-Î² inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model. PLoS ONE, 2021, 16, e0252620.	1.1	16
220	To Go or Not to Go?â€"Targeting Tregs Traveling in Tumors. Cancer Research, 2021, 81, 2817-2819.	0.4	4

#	Article	IF	Citations
221	Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. Cell, 2021, 184, 3998-4015.e19.	13.5	92
222	Cancer Immunotherapies: From Efficacy to Resistance Mechanisms â€“ Not Only Checkpoint Matters. Frontiers in Immunology, 2021, 12, 690112.	2.2	42
223	Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report. Anticancer Research, 2021, 41, 3699-3706.	0.5	5
224	Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma. Cancers, 2021, 13, 3666.	1.7	25
225	Comparing immunotherapies to other frequently used treatments of gastric cancer. Expert Review of Clinical Pharmacology, 2021, 14, 1221-1232.	1.3	2
226	Inflammation Determines the Capacity of Allogenic Endothelial Cells to Regulate Human Treg Expansion. Frontiers in Immunology, 2021, 12, 666531.	2.2	14
227	Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. , 2021, 9, e002591.		105
228	Breast cancer metastasis: immune profiling of lymph nodes reveals exhaustion of effector T cells and immunosuppression. Molecular Oncology, 2022, 16, 88-103.	2.1	18
229	Hyperprogression under immunotherapy: a new form of immunotherapy response?â€"a narrative literature review. Translational Lung Cancer Research, 2021, 10, 3276-3291.	1.3	15
230	Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 3001-3013.	2.0	17
231	Impaired function of PD-1+ follicular regulatory T cells in systemic lupus erythematosus. Clinical and Experimental Immunology, 2021, 206, 28-35.	1.1	12
232	The Cancer-Immunity Cycle in Multiple Myeloma. ImmunoTargets and Therapy, 2021, Volume 10, 247-260.	2.7	11
233	Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors. Frontiers in Pharmacology, 2021, 12, 678409.	1.6	15
234	Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer. , 0, , .		4
236	Conversion surgery of Stage IV gastric cancer with peritoneal dissemination after nivolumab. International Cancer Conference Journal, 2021, 10, 280-284.	0.2	6
237	PDâ€1â€induced proliferating T cells exhibit a distinct transcriptional signature. Immunology, 2021, 164, 555-568.	2.0	5
238	Volume control: Turning the dial on regulatory TÂcells. Cell, 2021, 184, 3847-3849.	13.5	4
239	Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors. Cancer Immunology, Immunotherapy, 2022, 71, 579-588.	2.0	27

#	Article	IF	Citations
240	Targeting cancer associated fibroblasts to enhance immunotherapy: emerging strategies and future perspectives. Oncotarget, 2021, 12, 1427-1433.	0.8	19
241	A narrative review of tumor heterogeneity and challenges to tumor drug therapy. Annals of Translational Medicine, 2021, 9, 1351-1351.	0.7	27
242	Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Antiâ€“Programmed Cell Deathâ€1 in HCC. Hepatology, 2021, 74, 2544-2560.	3.6	144
243	A mechanistic systems pharmacology modeling platform to investigate the effect of PD-L1 expression heterogeneity and dynamics on the efficacy of PD-1 and PD-L1 blocking antibodies in cancer. Journal of Theoretical Biology, 2021, 522, 110697.	0.8	1
244	Testicular Diffuse Large B-Cell Lymphomaâ€"Clinical, Molecular, and Immunological Features. Cancers, 2021, 13, 4049.	1.7	11
245	Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives. Frontiers in Immunology, 2021, 12, 713358.	2.2	10
246	Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models. Science Translational Medicine, 2021, 13, .	5.8	44
247	Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?. Journal of Thoracic Oncology, 2021, 16, 1267-1288.	0.5	77
248	Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report. Frontiers in Oncology, 2021, 11, 756365.	1.3	3
249	Layilin Anchors Regulatory T Cells in Skin. Journal of Immunology, 2021, 207, 1763-1775.	0.4	5
250	Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B. Journal of Hepatology, 2022, 76, 148-159.	1.8	59
251	Immune checkpoint blockade impairs immunosuppressive mechanisms of regulatory T cells in B-cell lymphoma. Translational Oncology, 2021, 14, 101170.	1.7	5
252	PD-1/PD-L1 Inhibitors versus Chemotherapy for Previously Treated Advanced Gastroesophageal Cancer: A Meta-Analysis of Randomized Controlled Trials. Journal of Oncology, 2021, 2021, 1-11.	0.6	5
253	An oral cancer vaccine using a Bifidobacterium vector suppresses tumor growth in a syngeneic mouse bladder cancer model. Molecular Therapy - Oncolytics, 2021, 22, 592-603.	2.0	8
254	Curcumin analog GOâ€Y030 boosts the efficacy of antiâ€PDâ€1 cancer immunotherapy. Cancer Science, 2021, 112, 4844-4852.	1.7	21
256	PD-1-stimulated TÂcell subsets are transcriptionally and functionally distinct. IScience, 2021, 24, 103020.	1.9	8
257	Role of CD4⁺CD25⁺FOXP3⁺T_{Reg}cells on tumor immunity. Immunological Medicine, 2022, 45, 94-107.	1.4	12
258	Systematic analysis of CD39, CD103, CD137, and PDâ€1 as biomarkers for naturally occurring tumor antigenâ€specific TILs. European Journal of Immunology, 2022, 52, 96-108.	1.6	26

#	Article	IF	Citations
259	TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704). Clinical Cancer Research, 2021, 27, 6709-6715.	3.2	20
260	Hsa_circ_0136666 activates Treg-mediated immune escape of colorectal cancer via miR-497/PD-L1 pathway. Cellular Signalling, 2021, 86, 110095.	1.7	27
261	CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells. Nature Communications, 2021, 12, 5764.	5.8	38
262	Antitumour immunity regulated by aberrant ERBB family signalling. Nature Reviews Cancer, 2021, 21, 181-197.	12.8	141
263	Hyperprogression: A novel response pattern under immunotherapy. Clinical and Translational Medicine, 2020, 10, e167.	1.7	22
264	Janus or Hydra: The Many Faces of T Helper Cells in the Human Tumour Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1224, 35-51.	0.8	10
265	Regulatory T Cells in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1273, 105-134.	0.8	14
266	Double immune checkpoint blockade in advanced NSCLC. Critical Reviews in Oncology/Hematology, 2020, 152, 102980.	2.0	12
270	Immuneâ€checkpoint molecules on regulatory Tâ€cells as a potential therapeutic target in head and neck squamous cell cancers. Cancer Science, 2020, 111, 1943-1957.	1.7	24
271	Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model. , 2020, 8, e001513.		17
272	Regulatory T Cells and Human Disease. Annual Review of Immunology, 2020, 38, 541-566.	9.5	552
273	Immunodynamics of explanted human tumors for immunoâ€oncology. EMBO Molecular Medicine, 2021, 13, e12850.	3.3	9
274	Identifying hub genes of clear cell renal cell carcinoma associated with the proportion of regulatory T cells by weighted gene co-expression network analysis. Aging, 2019, 11, 9478-9491.	1.4	13
275	Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?. , 2020, 3, 276-286.		3
276	Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 287-302.	0.7	20
277	Current Progresses of Functional Nanomaterials for Imaging Diagnosis and Treatment of Melanoma. Current Topics in Medicinal Chemistry, 2019, 19, 2494-2506.	1.0	6
278	Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy. Cancers, 2021, 13, 48.	1.7	20
279	Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy. Immune Network, 2020, 20, e8.	1.6	19

#	Article	IF	Citations
280	Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench. Oncotarget, 2021, 13, 13-15.	0.8	0
281	Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia. Cancer Research Communications, 2021, 1, 30-40.	0.7	10
282	Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors. Frontiers in Cell and Developmental Biology, 2021, 9, 738373.	1.8	15
283	Enhanced Gut-Homing Dynamics and Pronounced Exhaustion of Mucosal and Blood CD4+ T Cells in HIV-Infected Immunological Non-Responders. Frontiers in Immunology, 2021, 12, 744155.	2.2	3
284	PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer. Cancer Immunology, Immunotherapy, 2021, , 1.	2.0	1
285	Antiâ€"PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells. Journal of Immunology, 2021, 207, 2598-2607.	0.4	10
286	AMPK promotes antitumor immunity by downregulating PD-1 in regulatory T cells via the HMGCR/p38 signaling pathway. Molecular Cancer, 2021, 20, 133.	7.9	29
287	Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab. Cureus, 2019, 11, e4862.	0.2	3
289	Immune checkpoint blockade in allogeneic hematopoietic cell transplantation. Journal of Hematopoietic Cell Transplantation, 2020, 9, 13-22.	0.1	0
291	Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma. Cancers, 2021, 13, 5405.	1.7	6
292	Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients. Science Translational Medicine, 2021, 13, eabf5264.	5.8	40
293	Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs. Immune Network, 2020, 20, e48.	1.6	10
294	å…ç–«ãƒã‚§ãƒƒã‚¯ãƒã‚¤ãƒ³ãƒˆé˜»å®³è–¬ã®è€æ€§ãƒ¡ã‚«ãƒ‹ã‚ºãƒ ã‚'è€ƒãˆã‚‹. Skin Cancer, 2021, 36, 127-132.	0.1	0
296	Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer. Frontiers in Oncology, 2021, 11, 761110.	1.3	5
297	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. Journal of Histochemistry and Cytochemistry, 2022, 70, 53-81.	1.3	6
298	Clinical and Immunological Effects of p53-Targeting Vaccines. Frontiers in Cell and Developmental Biology, 2021, 9, 762796.	1.8	12
299	The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. Science Immunology, 2021, 6, eabf4034.	5.6	22
301	Review: Gastric cancer: Basic aspects. Helicobacter, 2020, 25, e12739.	1.6	3

#	Article	IF	Citations
302	Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer. Asia-Pacific Journal of Oncology Nursing, 2021, 8, 586-590.	0.7	0
303	The role of myeloid-derived suppressor cells in lung cancer and targeted immunotherapies. Expert Review of Anticancer Therapy, 2022, 22, 65-81.	1.1	9
304	Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PD-L1 Therapy. Biochemistry (Moscow), 2021, 86, 1461-1468.	0.7	2
305	Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma. Expert Opinion on Emerging Drugs, 2021, 26, 385-400.	1.0	4
306	ÐŸÐ°Ñ€Ð°Ð¼ÐµÑ‚Ñ€Ñ‹ Ð¼Ð¸ÐºÑ€Ð¾Ð¾ÐºÑ€ÑƒÐ¶ÐµÐ½Ð¸Ñ• Ð¾Ð¿ÑƒÑ…Ð¾Ð»Ð¸ Ð¾Ð¿Ñ€ÐµÐ´ÐµÐ»ÑÑŽÑ‚ Ñ„Ñ„ÐµÐºÑ‚Ð¸Ð²Ð	0.0	0
307	Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. Pharmacological Research, 2022, 175, 105997.	3.1	43
308	238â€…Meta-analysis on the incidence of hyperprogressive disease during immune checkpoint inhibitor therapy. , 2021, 9, A254-A256.		0
309	A deficient MIF-CD74 signaling pathway may play an important role in immunotherapy-induced hyper-progressive disease. Cell Biology and Toxicology, 2021, , 1.	2.4	5
310	Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 767466.	1.8	13
311	The Emerging Interplay Between Recirculating and Tissue-Resident Memory T Cells in Cancer Immunity: Lessons Learned From PD-1/PD-L1 Blockade Therapy and Remaining Gaps. Frontiers in Immunology, 2021, 12, 755304.	2.2	2
312	Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. Cell Reports, 2021, 37, 110021.	2.9	21
313	Mutant IDH Inhibits IFNÎ³â€“TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma. Cancer Discovery, 2022, 12, 812-835.	7.7	55
314	OUP accepted manuscript. Japanese Journal of Clinical Oncology, 2022, , .	0.6	5
315	Resistance to Immunotherapy: Mechanisms and Means for Overcoming. Advances in Experimental Medicine and Biology, 2021, 1342, 45-80.	0.8	2
316	HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncology, The, 2022, 23, 172-184.	5.1	58
317	Biomarkers for predicting the efficacy of immune checkpoint inhibitors. Journal of Cancer, 2022, 13, 481-495.	1.2	12
318	Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments. , 2022, 10, e003735.		14
319	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. Biomedicine and Pharmacotherapy, 2022, 146, 112516.	2.5	38

#	Article	IF	Citations
320	The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. Immunotherapy, 2022, 14, 155-167.	1.0	7
321	Immunotherapy of Cancer by Targeting Regulatory T cells. International Immunopharmacology, 2022, 104, 108469.	1.7	46
322	Perspective on the Immunotherapy of Gastric Cancer. , 2021, , 89-102.		0
323	Lactic acid promotes PD-1 expression in regulatory TÂcells in highly glycolytic tumor microenvironments. Cancer Cell, 2022, 40, 201-218.e9.	7.7	266
324	Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma. Bioscience Reports, 2022, 42, .	1.1	13
325	Targeting regulatory T cells in antiâ€PDâ€1/PDâ€L1 cancer immunotherapy. Scandinavian Journal of Immunology, 2022, 95, e13129.	1.3	27
326	Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy. Future Medicinal Chemistry, 2022, 14, 97-113.	1.1	10
327	Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	5
328	Dangerous dynamic duo: Lactic acid and PD-1 blockade. Cancer Cell, 2022, 40, 127-130.	7.7	10
329	Antiâ€PDâ€L1/TGFâ€Î²R fusion protein (SHRâ€1701) overcomes disrupted lymphocyte recoveryâ€induced resistance to PDâ€1/PDâ€L1 inhibitors in lung cancer. Cancer Communications, 2022, 42, 17-36.	3.7	30
330	Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy. BMC Cancer, 2022, 22, 100.	1.1	4
331	CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor. Scientific Reports, 2022, 12, 1100.	1.6	7
332	Non-gestational choriocarcinoma with hyperprogression on pembrolizumab: A case report and review of the literature. Gynecologic Oncology Reports, 2022, 39, 100923.	0.3	6
333	TGF-Î² and Cancer Immunotherapy. Biological and Pharmaceutical Bulletin, 2022, 45, 155-161.	0.6	20
334	Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. Journal of Clinical Investigation, 2022, 132, .	3.9	38
335	PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted TÂcell clonotypes. Cell Reports, 2022, 38, 110331.	2.9	45
336	Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 147-164.	0.9	5
337	CD8⁺PD-1⁺ to CD4⁺PD-1⁺ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers. , 2022, 10, e004012.		16

#	Article	IF	Citations
338	CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	68
339	Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer. Seminars in Cancer Biology, 2022, 86, 542-565.	4.3	51
340	Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases. Cancers, 2022, 14, 792.	1.7	8
341	T cell costimulation, checkpoint inhibitors and anti-tumor therapy. Journal of Biosciences, 2020, 45, .	0.5	6
342	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. Immune Network, 2022, 22, e2.	1.6	53
343	Effects of PD-1 Signaling on Immunometabolic Reprogramming. Immunometabolism, 2022, 4, .	0.7	10
344	Interlocked feedback loops balance the adaptive immune response. Mathematical Biosciences and Engineering, 2022, 19, 4084-4100.	1.0	0
345	The New Era of Immunotherapy in Gastric Cancer. Cancers, 2022, 14, 1054.	1.7	68
346	Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity. Frontiers in Immunology, 2022, 13, 835690.	2.2	9
347	Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies. Frontiers in Cell and Developmental Biology, 2022, 10, 830208.	1.8	13
348	Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond. Cancers, 2022, 14, 1408.	1.7	2
349	Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group. Brain Tumor Pathology, 2022, 39, 139-150.	1.1	4
350	A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nature Immunology, 2022, 23, 660-670.	7.0	191
351	Nanoliposome C6â€Ceramide in combination with antiâ€CTLA4 antibody improves antiâ€tumor immunity in hepatocellular cancer. FASEB Journal, 2022, 36, e22250.	0.2	10
352	Current Understanding and Future Perspectives on Hyperprogressive Disease Highlight the Tumor Microenvironment. Journal of Clinical Pharmacology, 2022, 62, 1059-1078.	1.0	0
353	Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions. Seminars in Cancer Biology, 2022, 86, 532-541.	4.3	14
354	Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review. Frontiers in Nutrition, 2022, 9, 810472.	1.6	5
355	Safe Concurrent Use of Anti-tuberculosis Drugs and Pembrolizumab in a Patient with Non-small-cell Lung Cancer Who Was Infected with <i>Mycobacterium tuberculosis</i>. Internal Medicine, 2022, 61, 1039-1042.	0.3	3

#	Article	IF	Citations
356	Large-Scale Single-Cell and Bulk Sequencing Analyses Reveal the Prognostic Value and Immune Aspects of CD147 in Pan-Cancer. Frontiers in Immunology, 2022, 13, 810471.	2.2	16
357	Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model. Experimental Hematology and Oncology, 2022, 11, 20.	2.0	6
358	Exosomal circGSE1 promotes immune escape of hepatocellular carcinoma by inducing the expansion of regulatory T cells. Cancer Science, 2022, 113, 1968-1983.	1.7	38
359	Imaging immunity in patients with cancer using positron emission tomography. Npj Precision Oncology, 2022, 6, 24.	2.3	13
360	Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials. , 2022, 10, e004273.		10
361	Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. Hepatology Research, 2022, 52, 298-307.	1.8	31
362	Cancer-immunotherapy biomarkers in the tumor microenvironment. Okayama Igakkai Zasshi, 2021, 133, 151-157.	0.0	0
363	Interleukinâ€2â€inducible Tâ€cell kinase (Itk) signaling regulates potent noncanonical regulatory T cells. Clinical and Translational Medicine, 2021, 11, e625.	1.7	10
364	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nature Reviews Drug Discovery, 2022, 21, 509-528.	21.5	201
365	Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab. Nature Communications, 2021, 12, 7280.	5.8	11
367	TGFÎ²: Signaling Blockade for Cancer Immunotherapy. Annual Review of Cancer Biology, 2022, 6, .	2.3	7
368	Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer. Asia-Pacific Journal of Oncology Nursing, 2021, 8, 586-590.	0.7	1
369	Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity. MedComm, 2022, 3, e137.	3.1	11
370	Tumor-associated macrophages promote intratumoral conversion of conventional CD4⁺ T cells into regulatory T cells via PD-1 signalling. OncoImmunology, 2022, 11, 2063225.	2.1	14
371	CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab. BMC Cancer, 2022, 22, 418.	1.1	3
372	Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. Haematologica, 2022, 107, 2418-2431.	1.7	14
373	PD-L1â€“PD-1 interactions limit effector regulatory T cell populations at homeostasis and during infection. Nature Immunology, 2022, 23, 743-756.	7.0	47
374	PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration. Nature Communications, 2022, 13, 2176.	5.8	18

#	Article	IF	Citations
375	Comparison Between Nr4a Transcription Factor Regulation and Function in Lymphoid and Tumor Treg Cells. Frontiers in Immunology, 2022, 13, 866339.	2.2	4
376	Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies. Biomedicine and Pharmacotherapy, 2022, 150, 112949.	2.5	6
385	A variety of â€˜exhaustedâ€™ T cells in the tumor microenvironment. International Immunology, 2022, 34, 563-570.	1.8	13
386	Intestinal stents: Structure, functionalization and advanced engineering innovation. , 2022, 137, 212810.		4
387	Tumor-Associated Regulatory T Cells in Non-Small-Cell Lung Cancer: Current Advances and Future Perspectives. Journal of Immunology Research, 2022, 2022, 1-8.	0.9	13
388	A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer. Translational Lung Cancer Research, 2022, 11, 607-616.	1.3	5
389	Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2022, 28, 3990-4002.	3.2	15
390	T Lymphocyte Exhaustion During Human and Experimental Visceral Leishmaniasis. Frontiers in Immunology, 2022, 13, 835711.	2.2	14
391	Immune checkpoints in T cells during oncogenic Î³â€herpesvirus infections. Journal of Medical Virology, 2023, 95, .	2.5	3
392	Cancer evolution: special focus on the immune aspect of cancer. Seminars in Cancer Biology, 2022, , .	4.3	4
393	Comprehensive phenotyping of mouse regulatory T cells relevant to viral infections. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2022, , .	1.1	1
394	Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy. Cells, 2022, 11, 1758.	1.8	3
395	Regulation of Treg Cell Metabolism and Function in Non-Lymphoid Tissues. Frontiers in Immunology, 0, 13, .	2.2	8
396	Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-Î² signaling in regulatory TÂcells. Cell Reports, 2022, 39, 110986.	2.9	82
397	Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. , 2022, 10, e004984.		28
398	Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas. Cancers, 2022, 14, 3037.	1.7	6
399	Hyperprogression on anti-PD-1 treatment. Is subsequent therapy feasible? A case report and review of the literature. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 0, , .	0.2	0
400	Excessive immunosuppression by regulatory T cells antagonizes T cell response to schistosome infection in PD-1-deficient mice. PLoS Pathogens, 2022, 18, e1010596.	2.1	7

#	Article	IF	Citations
401	Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-Î² degradation. Nature Communications, 2022, 13, .	5.8	26
402	Deconstructing T Cell Clonal Dynamics in Response to Immune-Checkpoint Blockade. SSRN Electronic Journal, 0, , .	0.4	0
403	Independent Prognostic Significance and Immunotherapy Response of Overexpressed ECE2 in Lung Adenocarcinoma. SSRN Electronic Journal, 0, , .	0.4	0
404	Metastatic Clear Cell Renal Cell Carcinoma to Pancreas and Distant Organs 24 Years After Radical Nephrectomy: A Case Report and Literature Review. Frontiers in Surgery, 0, 9, .	0.6	7
405	Revisiting PD-1/PD-L pathway in T and B cell response: Beyond immunosuppression. Cytokine and Growth Factor Reviews, 2022, 67, 58-65.	3.2	15
406	<i>PAPPA2</i> mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and <scp>nonâ€small</scp> cell lung cancer. Cell Proliferation, 2022, 55, .	2.4	5
407	Gallic acid induces T-helper-1-like T_{reg} cells and strengthens immune checkpoint blockade efficacy. , 2022, 10, e004037.		16
408	Mechanisms of resistance to immune checkpoint inhibitors. Cancer Science, 2022, 113, 3303-3312.	1.7	12
409	Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions. Frontiers in Immunology, 0, 13, .	2.2	6
410	Stromal and Immune Cell Dynamics in Tumor Associated Tertiary Lymphoid Structures and Anti-Tumor Immune Responses. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	3
411	Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. Journal of Hematology and Oncology, 2022, 15, .	6.9	58
412	Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. European Journal of Cancer, 2022, 172, 387-399.	1.3	4
413	Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 3139-3147.	1.2	7
414	Regulatory Tâ€cell development in the tumor microenvironment. European Journal of Immunology, 2022, 52, 1216-1227.	1.6	29
415	Mesenchymal stem cells-based therapy in liver diseases. Molecular Biomedicine, 2022, 3, .	1.7	4
416	Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease. Frontiers in Immunology, 0, 13, .	2.2	10
417	Monocarboxylate transporter upregulation in induced regulatory T cells promotes resistance to anti-PD-1 therapy in hepatocellular carcinoma patients. Frontiers in Oncology, 0, 12, .	1.3	3
418	PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy. Cancer Immunology, Immunotherapy, 2023, 72, 633-645.	2.0	11

#	Article	IF	Citations
419	Antitumor efficacy of ⁹⁰Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors. , 2022, 10, e005060.		7
420	Tumour Derived Extracellular Vesicles: Challenging Target to Blunt Tumour Immune Evasion. Cancers, 2022, 14, 4020.	1.7	6
421	Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects. Current Medicinal Chemistry, 2023, 30, 3215-3237.	1.2	3
422	Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor. BMC Cancer, 2022, 22, .	1.1	3
423	An immunotherapy response prediction model derived from proliferative CD4+ T cells and antigen-presenting monocytes in ccRCC. Frontiers in Immunology, 0, 13, .	2.2	7
424	The changes in peripheral blood Th17 and Treg ratios in Hashimotoâ€™s thyroiditis are accompanied by differential PD-1/PD-L1 expression. Frontiers in Endocrinology, 0, 13, .	1.5	1
425	Myc inhibition tips the immune balance to promote antitumor immunity. , 2022, 19, 1030-1041.		4
427	Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma. Gastroenterology, 2023, 164, 72-88.e18.	0.6	48
428	Solid-type poorly differentiated adenocarcinoma of the stomach: A characteristic morphology reveals a distinctive immunoregulatory tumor microenvironment. Pathology Research and Practice, 2022, 238, 154124.	1.0	3
429	A novel prognostic index of stomach adenocarcinoma based on immunogenomic landscape analysis and immunotherapy options. Experimental and Molecular Pathology, 2022, 128, 104832.	0.9	11
430	CXCR3 Expression in Regulatory T Cells Drives Interactions With Dendritic Cells in Tumors to Limit CD8 ⁺ T Cell Tumor Immunity. SSRN Electronic Journal, 0, , .	0.4	0
431	Therapeutic Targeting of Tumor-Infiltrating Regulatory T Cells in Breast Cancer. Cancer Research, 2022, 82, 3868-3879.	0.4	8
432	Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy. Biomarker Research, 2022, 10, .	2.8	22
433	Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in NaÃ¯ve and Anti-PD-1 Resistant CT26-Bearing Mice. International Journal of Molecular Sciences, 2022, 23, 10677.	1.8	3
434	Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors. International Journal of Molecular Sciences, 2022, 23, 11080.	1.8	8
435	Regulatory T Cells in Pancreatic Cancer: Of Mice and Men. Cancers, 2022, 14, 4582.	1.7	5
436	Anti-PD-1 antibody-activated Th17 cells subvert re-invigoration of antitumor cytotoxic T-lymphocytes via myeloid cell-derived COX-2/PGE2. Cancer Immunology, Immunotherapy, 0, , .	2.0	2
437	Engineered Hybrid Treg-Targeted Nanosomes Restrain Lung Immunosuppression by Inducing Intratumoral CD8+T Cell Immunity. International Journal of Nanomedicine, 0, Volume 17, 4449-4468.	3.3	2

#	Article	IF	Citations
439	Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer. Frontiers in Immunology, 0, 13, .	2.2	19
440	Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment. Frontiers in Immunology, 0, 13, .	2.2	17
441	miR-aculous new avenues for cancer immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	0
442	A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study. Cancer Immunology, Immunotherapy, 2023, 72, 827-840.	2.0	3
443	Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test. Diagnostic Pathology, 2022, 17, .	0.9	6
444	Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression?. World Journal of Clinical Oncology, 2022, 13, 729-737.	0.9	0
445	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. Frontiers in Immunology, 0, 13, .	2.2	6
446	Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment. Frontiers in Immunology, 0, 13, .	2.2	12
447	Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy. Cancer Immunology Research, 2022, 10, 1386-1397.	1.6	18
448	Breast cancers co-opt normal mechanisms of tolerance to promote immune evasion and metastasis. American Journal of Physiology - Cell Physiology, 2022, 323, C1475-C1495.	2.1	6
449	A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained effector functions. Blood Advances, 2022, 6, 6093-6107.	2.5	6
450	Inhibition of NF-Î°B DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation. Molecular Cancer Therapeutics, 2022, 21, 1798-1809.	1.9	3
451	BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors. Science Immunology, 2022, 7, .	5.6	23
452	Altered acetyl-CoA metabolism presents a new potential immunotherapy target in the obese lung microenvironment. Cancer & Metabolism, 2022, 10, .	2.4	2
453	Translational Research in Cancer Immunotherapies. Japanese Journal of Lung Cancer, 2022, 62, 363-370.	0.0	0
454	Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy. International Journal of Molecular Sciences, 2022, 23, 13241.	1.8	9
455	Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer. Cancers, 2022, 14, 4885.	1.7	5
456	Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1. , 2022, 19, 1290-1301.		13

#	Article	IF	Citations
457	From thymus to tissues and tumors: AÂreview of T-cell biology. Journal of Allergy and Clinical Immunology, 2023, 151, 81-97.	1.5	14
458	VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated. Life Sciences, 2022, 310, 121083.	2.0	19
459	Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model. Frontiers in Medicine, 0, 9, .	1.2	1
460	Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade. Cells, 2022, 11, 3534.	1.8	1
461	Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. OncoImmunology, 2022, 11, .	2.1	13
462	Current developments in gastric cancer: from molecular profiling to treatment strategy. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 155-170.	8.2	61
463	Dysfunctional phenotype of systemic and pulmonary regulatory T cells associate with lethal <scp>COVID</scp>â€19 cases. Immunology, 2023, 168, 684-696.	2.0	6
464	T-cell engaging poly(lactic-co-glycolic acid) nanoparticles as a modular platform to induce a potent cytotoxic immunogenic response against PD-L1 overexpressing cancer. Biomaterials, 2022, 291, 121911.	5.7	11
465	Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy. Seminars in Immunopathology, 0, , .	2.8	2
466	Immune profile analysis of peripheral blood and tumors of lung cancer patients treated with immune checkpoint inhibitors. Translational Lung Cancer Research, 2022, 11, 2192-2207.	1.3	1
467	Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during antiâ€"PD-1 immunotherapy. Science Translational Medicine, 2022, 14, .	5.8	14
468	Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumor-infiltrating immune cells in non-small cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	1
469	Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?. Frontiers in Oncology, 0, 12, .	1.3	0
470	Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study. Frontiers in Immunology, 0, 13, .	2.2	6
471	Reinventing the human tuberculosis (TB) granuloma: Learning from the cancer field. Frontiers in Immunology, 0, 13, .	2.2	8
472	Niâ€Alginate Hydrogel Microspheres with Sustained Interleukin 2 Release to Boost Cytokineâ€Based Cancer Immunotherapy. Advanced Functional Materials, 2023, 33, .	7.8	6
473	Tolerance to 2,4-Dinitrofluorobenzeneâ€'Induced Contact Hypersensitivity Is Mediated by CD73-Expressing Tissue-Homing Regulatory T Cells. Journal of Investigative Dermatology, 2023, 143, 1011-1022.e8.	0.3	3
474	LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice. JACC: CardioOncology, 2022, 4, 635-645.	1.7	4

#	Article	IF	Citations
475	Trametinib improves Treg selectivity of anti-CCR4 antibody by regulating CCR4 expression in CTLs in oral squamous cell carcinoma. Scientific Reports, 2022, 12, .	1.6	1
476	Significance of regulatory T cells in cancer immunology and immunotherapy. Experimental Dermatology, 2023, 32, 256-263.	1.4	3
477	Resistance to immune checkpoint inhibitors and the tumor microenvironment. Experimental Dermatology, 2023, 32, 240-249.	1.4	5
478	Foods may modify responsiveness to cancer immune checkpoint blockers by altering both the gut microbiota and activation of estrogen receptors in immune cells. , 0, 1, .		2
479	PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	36
480	Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. Nature Cancer, 2022, 3, 1513-1533.	5.7	20
481	In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways. Frontiers in Immunology, 0, 13, .	2.2	6
482	Check(point) yourself before you wreck yourself in tumors. Nature Immunology, 2023, 24, 10-11.	7.0	0
483	A nanotherapeutic system for gastric cancer suppression by synergistic chemotherapy and immunotherapy based on iPSCs and DCs exosomes. Cancer Immunology, Immunotherapy, 2023, 72, 1673-1683.	2.0	4
484	Review to Understand the Crosstalk between Immunotherapy and Tumor Metabolism. Molecules, 2023, 28, 862.	1.7	4
485	Targeting regulatory T cells in gastric cancer: Pathogenesis, immunotherapy, and prognosis. Biomedicine and Pharmacotherapy, 2023, 158, 114180.	2.5	5
486	Balancing the Risk of Adverse Events against the Efficacy of Immunotherapy in Advanced Thymic Epithelial Tumors. Cancers, 2023, 15, 289.	1.7	2
487	Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells. Nature Immunology, 2023, 24, 148-161.	7.0	26
488	Single-cell characterization of antiâ€“LAG-3 and antiâ€“PD-1 combination treatment in patients with melanoma. Journal of Clinical Investigation, 2023, 133, .	3.9	20
489	Epithelialâ€“Mesenchymal Transition Phenotype and Peritumoral Immune Cell Infiltration in Advanced Biliary Tract Cancer. Anticancer Research, 2023, 43, 645-652.	0.5	2
490	CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy. Clinical Cancer Research, 2023, 29, 1794-1806.	3.2	4
491	Paradoxical cancer cell stimulation by IFNÎ³ drives tumor hyperprogression upon checkpoint blockade immunotherapy. Cancer Cell, 2023, 41, 229-231.	7.7	4
492	Advances in Immunotherapy for Hepatocellular Carcinoma. Cancers, 2023, 15, 2070.	1.7	2

#	Article	IF	Citations
493	The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases. , 2023, 245, 108399.		8
494	The evolving landscape of PCSK9 inhibition in cancer. European Journal of Pharmacology, 2023, 949, 175721.	1.7	7
495	JAML immunotherapy targets recently activated tumor-infiltrating CD8+ TÂcells. Cell Reports, 2023, 42, 112040.	2.9	2
496	Regulatory cells and the effect of cancer immunotherapy. Molecular Cancer, 2023, 22, .	7.9	34
497	Activated CTLAâ€4â€independent immunosuppression of Treg cells disturbs CTLAâ€4 blockadeâ€mediated antitumor immunity. Cancer Science, 2023, 114, 1859-1870.	1.7	6
498	Learning from the nexus of autoimmunity and cancer. Immunity, 2023, 56, 256-271.	6.6	4
499	TCF-1 negatively regulates the suppressive ability of canonical and noncanonical Tregs. Journal of Leukocyte Biology, 2023, 113, 489-503.	1.5	1
500	Life-threatening â€œhyper-progressionâ€•on immunotherapy revealed as pseudo-progression in DNA mismatch repair deficiency: a case report. Journal of Gastrointestinal Oncology, 2023, 14, 435-441.	0.6	0
501	Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?. Frontiers in Immunology, 0, 14, .	2.2	5
502	Interactions between Platelets and Tumor Microenvironment Components in Ovarian Cancer and Their Implications for Treatment and Clinical Outcomes. Cancers, 2023, 15, 1282.	1.7	2
503	Crosstalk between microbiome, regulatory T cells and HCA2 orchestrates the inflammatory response in a murine psoriasis model. Frontiers in Immunology, 0, 14, .	2.2	2
504	Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence. Cancers, 2023, 15, 1314.	1.7	2
506	Next-generation immunotherapy: regulatory T-cells. Genes and Cells, 2021, 16, 16-32.	0.2	0
507	The hipotises of the immune system's role in carcinogenesis. Genes and Cells, 2021, 16, 82-91.	0.2	2
508	Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment. Hepatology, 2023, 78, 1402-1417.	3.6	4
509	The CXCL10/CXCR3 Pathway Contributes to the Synergy of Thermal Ablation and PD-1 Blockade Therapy against Tumors. Cancers, 2023, 15, 1427.	1.7	2
510	Targeting tumor microenvironment for non-small cell lung cancer immunotherapy. , 2023, , .		1
511	Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed deathâ€ligand 1 inhibitors in nonâ€“small cell lung cancer. Cancer, 2023, 129, 1319-1350.	2.0	3

#	Article	IF	Citations
512	Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy. Cell Chemical Biology, 2023, 30, 235-247.e12.	2.5	27
513	Translational Studies Using the MALT1 Inhibitor (<i>S</i>)-Mepazine to Induce Treg Fragility and Potentiate Immune Checkpoint Therapy in Cancer. Journal of Immunotherapy and Precision Oncology, 2023, 6, 61-73.	0.6	4
514	Chronic adrenergic stress and generation of <scp>myeloidâ€derived</scp> suppressor cells: Implications for cancer immunotherapy in dogs. Veterinary and Comparative Oncology, 2023, 21, 159-165.	0.8	2
515	PD-1 and CTLA-4 exert additive control of effector regulatory T cells at homeostasis. Frontiers in Immunology, 0, 14, .	2.2	3
516	Differential regulatory T cell signature after recovery from mild COVID-19. Frontiers in Immunology, 0, 14, .	2.2	2
517	Tumor-infiltrating regulatory TÂcells as targets of cancer immunotherapy. Cancer Cell, 2023, 41, 450-465.	7.7	60
518	Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitorsâ€"A 2023 Update. International Journal of Molecular Sciences, 2023, 24, 5643.	1.8	7
519	FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer. Cancers, 2023, 15, 1901.	1.7	1
521	Tregs dysfunction aggravates postoperative cognitive impairment in aged mice. Journal of Neuroinflammation, 2023, 20, .	3.1	5
522	CD4+ T cells in cancer. Nature Cancer, 2023, 4, 317-329.	5.7	68
523	Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	2.2	0
524	Genomic and Immune Features in an Intrahepatic Cholangiocarcinoma Patient with Microsatellite Instability-High Suffered Rapid Acquired Resistance to PD-1 Inhibitor. Liver Cancer, 2023, 12, 281-288.	4.2	1
525	Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice. BMC Gastroenterology, 2023, 23, .	0.8	0
526	Multiâ€omic and spatial dissection of immunotherapy response groups in nonâ€small cell lung cancer. Immunology, 2023, 169, 487-502.	2.0	5
527	Mechanism of inert inflammation in an immune checkpoint blockade-resistant tumor subtype bearing transcription elongation defects. Cell Reports, 2023, 42, 112364.	2.9	0
528	Neoadjuvant immune checkpoint blockade triggers persistent and systemic T _{reg} activation which blunts therapeutic efficacy against metastatic spread of breast tumors. OncoImmunology, 2023, 12, .	2.1	5
529	Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies. , 2023, 20, 694-713.		8
530	Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients. IScience, 2023, 26, 106720.	1.9	1

#	Article	IF	Citations
542	MDM2- an indispensable player in tumorigenesis. Molecular Biology Reports, 2023, 50, 6871-6883.	1.0	1
543	Immunology and immunotherapy in gastric cancer. Clinical and Experimental Medicine, 2023, 23, 3189-3204.	1.9	1
576	Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity. Cell Death and Disease, 2023, 14, .	2.7	6
600	FcÎ³ receptors and immunomodulatory antibodies in cancer. Nature Reviews Cancer, 2024, 24, 51-71.	12.8	3
622	What happens to regulatory T cells in multiple myeloma. Cell Death Discovery, 2023, 9, .	2.0	0
625	Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. Cell Death and Disease, 2024, 15, .	2.7	0
630	Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition. , 2024, 41, .		0